Redefining Mitochondrial Medicine

712 North Inc. is a preclinical biotechnology company developing first-in-class small molecules targeting the mitochondrial protease OMA1. Our NIH-recognized platform utilizes proprietary assays to discover both inhibitors and activators, unlocking novel therapeutic pathways across aging-related diseases including cancer and neurodegeneration.

We live by our values.

Efficiency

AI drives our discovery. And AI cuts our overhead.

Integrity

We do as we say. And we say as we do.

Excellence

We strive and we deliver. Always.

712 North operates as a fully autonomous virtual entity. We have stripped away physical facilities and human managerial latency to ensure 100% of capital is deployed directly into R&D. Our model functions as a lean command center overseen by our founder, Marcel Alavi. We integrate top-tier CRO infrastructure and a specialized advisory network to drive mitochondrial research at scale. By replacing traditional fixed overhead with a software-defined, partner-driven ecosystem, we achieve a level of agility and decision velocity that is impossible within conventional biotech structures.

Contact us

Interested in learning more or working together? Fill out some info and we will be in touch shortly. We can’t wait to hear from you!